Clinical Role - Specialty Pharmacy

Pharmacy Times® is a leader in providing expert insights and clinical updates to specialty pharmacists and reaches more than 200,000 pharmacy professionals in total.

Top news of the week from Specialty Pharmacy Times.
New Treatment for Adults with Partial-Onset Seizures
The FDA has approved cenobamate tablets (XCOPRI, SK Life Sciences) for treatment of partial-onset seizures in adults.
FDA Approves Acalabrutinib
Under a new international collaboration, the FDA has granted supplemental approval to acalabrutinib (Calquence, AstraZeneca) for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic leukemia.
 
The 48-week phase 4 study showed that tocilizumab was more effective than rituximab in patients with rheumatoid arthritis with low B cell levels in synovial tissue.
Top news of the day from across the health care landscape.
 
Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss the benefits of attending NASP during the NASP Annual Meeting in Washington, DC.
The FDA has granted approvel to Alnylam’s givosiran (Givlaari) for the treatment of adults with acute hepatic porphyria.
Durvalumab (Imfinzi, AstraZeneca) and tremelimumab plus chemotherapy improved progression-free survival in first-line stage 4 non-small cell lung cancer.
 
Top news of the day from across the health care landscape.
 
Top news of the day from across the health care landscape.
 
Researchers in the JADE MONO-1 study investigated whether patients aged 12 years and older with moderate to severe atopic dermatitis would achieve with abrocitinib could achieve clear or almost clear skin with abrocitinib.